Candidiasis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The candidiasis market size was valued at USD 2.83 billion in 2025 and is estimated to grow from USD 2.96 billion in 2026 to reach USD 3.91 billion by 2031, at a CAGR of 5.75% during the forecast period (2026-2031). This report is Segmented by Treatment Type (Antifungal Medications, Supportive Therapy), Drug Class (Azoles, Echinocandins, Polyenes, Glucan Synthase Inhibitors, Others), Clinical Indication, Route of Administration (Oral, Injectable, Topical, Vaginal), Patient Population, End User, Distribution Channel, and Geography (North America, Europe, Asia-Pacific, Middle East, South America)

Global Candidiasis Market Trends and Insights

Growing Immunocompromised and Critically Ill Patient Pool

The wider use of chemotherapy, biologic medicines, and transplant conditioning has increased the population vulnerable to candidiasis. A 2026 review estimated that invasive candidiasis complicated 7 episodes per 1,000 ICU admissions, while noting that diagnostic problems can lead to undercounting. The CDC identifies injection-drug use as a separate pathway for community-onset candidemia in the United States. This pathway extends risk beyond the conventional oncology and transplant populations, bringing younger adults with community-onset disease into a care pathway that can require specialized outpatient intravenous access rather than routine hospital formulary management alone, and the candidiasis market is affected because this broader population does not fit a single inpatient treatment or dispensing pattern. The candidiasis market, therefore, has demand across inpatient care, outpatient intravenous treatment, and oral step-down therapy. These patient groups can require specialized access to antifungals when care shifts outside hospitals, including coordinated pharmacy support, reliable follow-up, and treatment choices that fit the duration and intensity of the infection.

Rising Healthcare-Associated Candidemia and Invasive Candidiasis

Healthcare-associated candidemia remains a serious infection in intensive care settings. A 2026 Italian study of 179,590 ICU admissions from 2020 through 2024 found 50.3% in-hospital mortality for ICU-acquired candidemia, compared with 34.1% for comparable bacterial bloodstream infections. The study reported fluconazole resistance in 53.7% of Candida parapsilosis isolates, a species responsible for 33% of ICU candidemia episodes. It also reported average ICU stays of 44 days for candidemia and 36 days for bacterial bloodstream infections. The CDC stated that a candidemia episode added USD 6,000 to USD 29,000 in hospitalization costs. These clinical and cost pressures support hospital use of broad-spectrum echinocandins and newer treatments when resistance or treatment failure is a concern, because the financial and clinical effects of prolonged critical care can outweigh savings from an azole-first protocol.

Generic Price Erosion in High-Volume Azole Therapies

Fluconazole is available through 63 National Drug Code entries in the United States at USD 0.83 to USD 1.95 per unit. This low-price availability compresses average selling prices in the outpatient portion of the candidiasis market, even when the number of prescriptions and the underlying need for treatment remain significant across common forms of disease. Hospital formularies can retain generic azoles as initial treatments even when susceptibility testing supports a higher-cost alternative. Reimbursement systems do not always reward premium medicines without documented resistance. BARDA’s potential commitment of up to USD 268 million for fosmanogepix shows the role of public support in developing novel antifungal mechanisms. Stewardship policies and payer rules can also require formal resistance evidence before a pharmacy and therapeutics committee supports a premium antifungal, leaving hospitals to balance the price of a newer product against clinical risk and local susceptibility data.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Rapid Species Identification and Susceptibility Testing
• Mainstream Adoption of Outpatient Oral and Maintenance Therapies
• Limited Antifungal Development Incentives and Lengthy Clinical Trials

Segment Analysis

Antifungal medications accounted for 85.23% of the candidiasis market share in 2025, making them the main source of treatment revenue across outpatient cases, hospital care, and severe invasive infections. Supportive therapy is expected to expand at a 6.5% CAGR from 2026 through 2031. A 2026 review reported 57% in-hospital mortality for non-catheter-related candidemia and 42.9% for catheter-related disease. This difference has strengthened attention to catheter management, nutritional support, immune restoration, and source control in high-acuity care, where the clinical team must address infection management alongside the underlying conditions that make the patient vulnerable. The candidiasis market benefits when hospitals view supportive care as part of an integrated infection-management approach.

This creates demand for infection-control products and hospital supply services that sit beside antifungal prescribing. Ibrexafungerp shows how treatment categories are changing because it is an oral triterpenoid that inhibits 1,3-beta-D-glucan synthase. Its oral form differs from lipopeptide echinocandins used in hospital treatment. Surgical and procedural treatment remains a small part of care, mainly when deep peritoneal or cardiac candidiasis requires source control. Treatment selection depends on infection severity, the affected site, diagnostic confirmation, and a patient’s ability to receive medication outside the hospital.

Azoles held 42.35% of the candidiasis market share in 2025, supported by extensive prescribing of fluconazole and itraconazole. Generic products generate high volume but operate at commodity prices, while newer azoles can have higher pricing in selected invasive-fungal indications. Basilea stated in 2026 that Cresemba was the global revenue leader for invasive fungal infections. Oteseconazole also had FDA exclusivity through 2027 for recurrent vulvovaginal candidiasis. Susceptibility standards from EUCAST and CLSI guide escalation from azoles when resistance breakpoints are reached.

Glucan synthase inhibitors are forecast to grow at a 6% CAGR through 2031 in the candidiasis market. Ibrexafungerp supports this category through its use for vulvovaginal and recurrent vulvovaginal candidiasis. SCYNEXIS reported that SCY-247 received Qualified Infectious Disease Product and Fast Track designations and entered intravenous Phase 1 dosing in February 2026. Echinocandins include caspofungin, micafungin, and anidulafungin, which are guideline-endorsed treatments for invasive candidiasis. Rezafungin adds once-weekly dosing, while polyenes are reserved for severe refractory or pan-resistant infections because nephrotoxicity limits routine use.

Vulvovaginal candidiasis represented 35.56% of 2025 clinical-indication revenue in the candidiasis market. Its position reflects high prevalence, prescription, and over-the-counter treatment options, and dedicated recurrent-disease products. A 2-year VIOLET Phase 3 extension study published in November 2025 reported sustained efficacy for oteseconazole in recurrent disease. This clinical evidence may support future label updates or specialist prescribing. Oral and oropharyngeal disease remains common among people with HIV and patients receiving immunosuppressive cancer care, while esophageal disease can require systemic treatment when oral disease is more severe.

Invasive candidiasis is forecast to record a 6.25% CAGR from 2026 through 2031. The WHO identifies C. auris as a high-priority fungal pathogen because it can cause invasive disease and show resistance to antifungal medicines. This classification supports institutional attention to susceptibility-guided treatment. Cutaneous and urinary candidiasis are usually managed with topical treatment or short oral azole courses. Systemic and disseminated forms require intravenous antifungals in ICU settings and have the highest per-episode treatment value within the indication range.

Complete Report Scope:

• By Treatment Type
  • Antifungal Medications
  • Supportive Therapy
  • Surgical & Procedural Interventions
• By Drug Class
  • Azoles
  • Echinocandins
  • Polyenes
  • Glucan Synthase Inhibitors
  • Other Antifungals
• By Clinical Indication
  • Oral & Oropharyngeal Candidiasis
  • Esophageal Candidiasis
  • Vulvovaginal Candidiasis
  • Cutaneous Candidiasis
  • Urinary Candidiasis
  • Invasive Candidiasis
  • Systemic & Disseminated Candidiasis
• By Route of Administration
  • Oral
  • Injectable
  • Topical
  • Vaginal/Intravaginal
• By Patient Population
  • Adults
  • Pediatrics
  • Pregnant & Reproductive-Age Women
  • Older Adults
  • Immunocompromised Patients
• By End User
  • Hospitals
  • Specialty Clinics
  • Diagnostic Laboratories
  • Long-Term Care Facilities
  • Homecare Settings
  • Research Institutes & CROs
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Direct Institutional Procurement
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.11% of candidiasis revenue in 2025 and remained the largest regional market, supported by the United States as the central clinical and commercial reference point. The CDC estimates 25,000 candidemia cases each year in the United States, with an additional USD 6,000 to USD 29,000 in hospital costs per case, which supports the economic case for treatment in high-acuity settings. Mandatory C. auris reporting since 2019 and screening-case reporting since 2023 provide national case data, giving health systems a clearer view of exposure than many other regions. This surveillance supports investment in rapid diagnostics, susceptibility testing, and newer antifungals, particularly where resistant infections are documented. The FDA updated the REZZAYO prescribing label in December 2025, while Mundipharma plans an FDA supplemental application for HSCT prophylaxis in H2 2026.

Europe has varied C. auris conditions that are changing procurement priorities across national health systems and creating different needs for surveillance, infection control, and antifungal access. The ECDC’s 2024 survey found outbreaks in Cyprus, France, and Germany, while Greece, Italy, Romania, and Spain had endemic transmission through hospital networks. EU Greece, Italy, and Spain moved from the first documented case to endemicity over 5 to 7 years, which makes the experience in those countries relevant for states now managing more recent outbreaks. Germany completed a formal benefit assessment for rezafungin in 2024 under the SGB V orphan drug provision, and the 2025 international Candida guideline can guide ICU and hematology prescribing in the United Kingdom, France, Spain, and Italy.

Asia-Pacific is forecast to grow at an 8.2% CAGR from 2026 through 2031, the fastest regional rate in the candidiasis market, as critical care capacity expands and resistance complicates conventional azole use. A 2026 Chinese tertiary-hospital study found that candidemia incidence increased from 0.98% in 2015 to 1.69% in 2024, with persistently high azole resistance in C. tropicalis. A 2026 Northern India studyreported multidrug-resistant C. auris with high fluconazole resistance and reduced amphotericin B susceptibility, which can shift hospitals toward echinocandins. Oteseconazole’s April 2025 listing on China’s reimbursement drug list expanded access for recurrent vulvovaginal candidiasis, while Japan, South Korea, and Australia retain structured formulary access for premium antifungals. The Middle East and South America are smaller growth areas, supported by ICU expansion, HIV coinfection burden, and reported C. auris echinocandin resistance in South American hospital networks.

List of Companies Covered in this Report:

• Pfizer
• Merck
• Astellas Pharma
• Viatris
• Bayer
• SCYNEXIS
• Mycovia Pharmaceuticals
• Cidara Therapeutics, Inc.
• Melinta Therapeutics, LLC
• Basilea Pharmaceutica Ltd.
• Roche
• GlaxoSmithKline
• Novartis
• Teva Pharmaceutical Industries
• Cipla
• Lupin
• Biocon
• Torrent Pharmaceuticals
• NovaDigm Therapeutics, Inc.
• T2 Biosystems, Inc.
• bioM�rieux SA
• Associates of Cape Cod, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support